Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 3/20 | 0.33 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494637 | 1.00 | PKM (0.39) | PKMGPR119HDAC1HDAC6HDAC8 | |
| SCHEMBL3494766 | 0.82 | PKM (0.37) | PKMGPR119HDAC1HDAC6HDAC8 | |
| SCHEMBL3494769 | 0.82 | PKM (0.37) | PKMGPR119HDAC1HDAC6HDAC8 | |
| SCHEMBL3494448 | 0.82 | GPR119 (0.41) | GPR119SCD5 | |
| SCHEMBL3494444 | 0.82 | GPR119 (0.41) | GPR119SCD5 | |
| SCHEMBL3493790 | 0.78 | SCD5 (0.38) | PKMGPR119SCD5USP30 | |
| SCHEMBL3493792 | 0.78 | SCD5 (0.38) | PKMGPR119SCD5USP30 | |
| SCHEMBL13339882 | 0.71 | GPR119 (0.34) | PKMGPR119HDAC1HDAC6HDAC8 | |
| SCHEMBL743916 | 0.68 | IDO1 (0.44) | PKMGPR119HDAC1HDAC6HDAC8 | |
| SCHEMBL13339756 | 0.68 | GPR119 (0.36) | PKMGPR119NAMPTSCD5MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-06 | — | — | US | disclosed |
| EP-2123652-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113418-A1 | HETEROCYCLIC COMPOUND | ACACA, ACAT1, CPT1B | PKM 1044/4885GPR119 25/4885HDAC1 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.